Sharescart Research Club logo

Nath Bio-Genes Overview

Nath Bio-Genes (India) Ltd engages inside the production, processing, and advertising of hybrid and GM seeds in India and the world over. It operates in segments, Agricultural Activities and Trading Activities. The company gives seeds for cereals, which include maize, paddy, millet, wheat, and jowar; fruit seeds; fiber and oil seeds, consisting of cotton and mustard; and seeds for vegetables comprising chilli, okra, tomato, brinjal, bottle gourd, bitter gourd, sponge gourd, ridge gourd, cucumber, coriander, onion, sweet peeper, green peas, pum...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Nath Bio-Genes Key Financials

Market Cap ₹372 Cr.

Stock P/E 9.7

P/B 0.5

Current Price ₹196

Book Value ₹ 358.6

Face Value 10

52W High ₹238

Dividend Yield 1.02%

52W Low ₹ 126.8

Nath Bio-Genes Share Price

₹ | |

Volume
Price

Nath Bio-Genes Quarterly Price

Show Value Show %

Nath Bio-Genes Peer Comparison

Nath Bio-Genes Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 23 32 43 244 32 37 52 284 44 66
Other Income 0 0 0 0 0 0 4 2 2 2
Total Income 23 32 43 244 32 37 56 285 46 68
Total Expenditure 18 26 39 207 27 29 52 245 38 62
Operating Profit 5 6 4 37 5 9 4 40 8 5
Interest 2 3 1 2 3 4 1 3 4 5
Depreciation 1 1 1 1 1 1 1 1 1 1
Exceptional Income / Expenses 0 3 0 0 0 0 0 0 0 3
Profit Before Tax 2 5 2 34 1 4 2 36 3 2
Provision for Tax 0 1 1 0 -0 1 1 1 1 1
Profit After Tax 2 4 2 33 1 3 1 35 3 2
Adjustments 0 0 1 0 -0 0 1 2 0 -0
Profit After Adjustments 2 4 3 33 1 3 1 37 3 2
Adjusted Earnings Per Share 0.8 2 1.4 17.6 0.6 1.4 0.8 19.6 1.4 0.8

Nath Bio-Genes Profit & Loss

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 124 138 278 301 333 365 446
Other Income 1 1 2 1 1 5 10
Total Income 125 138 280 302 333 369 455
Total Expenditure 109 118 241 252 283 315 397
Operating Profit 16 20 39 50 51 55 57
Interest 2 4 11 10 9 11 13
Depreciation 5 5 3 3 3 4 4
Exceptional Income / Expenses 0 0 -89 0 3 1 3
Profit Before Tax 9 12 -63 36 42 41 43
Provision for Tax -0 1 4 1 2 2 4
Profit After Tax 9 12 -67 35 40 39 41
Adjustments 0 0 0 0 0 0 3
Profit After Adjustments 9 12 -67 35 40 39 43
Adjusted Earnings Per Share 0 0 -35.5 18.4 20.8 20.3 22.6

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 10% 10% 24% 0%
Operating Profit CAGR 8% 12% 28% 0%
PAT CAGR -3% 0% 34% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 25% 6% -11% 8%
ROE Average 6% 6% 4% 7%
ROCE Average 7% 7% 6% 8%

Nath Bio-Genes Balance Sheet

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 46 57 542 573 610 644
Minority's Interest 0 0 -0 0 0 0
Borrowings 1 1 1 0 5 13
Other Non-Current Liabilities 1 1 3 3 3 4
Total Current Liabilities 72 98 194 216 262 365
Total Liabilities 119 157 739 793 880 1026
Fixed Assets 21 38 245 244 249 250
Other Non-Current Assets 2 0 27 29 59 86
Total Current Assets 96 120 468 520 572 690
Total Assets 119 157 739 793 880 1026

Nath Bio-Genes Cash Flow

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 3 29 4 38 77
Cash Flow from Operating Activities 0 14 17 38 75 18
Cash Flow from Investing Activities 0 -21 -20 -3 -27 -4
Cash Flow from Financing Activities 0 6 -22 -2 -8 -2
Net Cash Inflow / Outflow 0 -1 -25 34 39 11
Closing Cash & Cash Equivalent 0 2 4 38 77 89

Nath Bio-Genes Ratios

# Mar 2012 Mar 2013 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0 0 -35.46 18.43 20.85 20.31
CEPS(Rs) 8.69 10.16 -33.84 20.01 22.56 22.32
DPS(Rs) 0 0 2 2 2 2
Book NAV/Share(Rs) 0 0 285.16 301.61 320.94 339.08
Core EBITDA Margin(%) 11.84 14.45 13.37 16.25 15.02 13.69
EBIT Margin(%) 8.78 11.6 -18.96 15.44 15.26 14.04
Pre Tax Margin(%) 7.32 8.93 -22.79 12 12.5 11.12
PAT Margin (%) 7.42 8.53 -24.21 11.62 11.91 10.58
Cash Profit Margin (%) 11.22 11.8 -23.1 12.62 12.89 11.62
ROA(%) 7.73 8.5 -15.03 4.57 4.74 4.05
ROE(%) 20.12 22.76 -22.48 6.28 6.7 6.15
ROCE(%) 19.09 23.88 -14.84 7.09 7.26 6.89
Receivable days 36.68 44.32 69.85 110.74 105.14 91.63
Inventory Days 193.69 189.43 195.06 259.3 240.4 284.23
Payable days 1576.65 -4219.16 1503.38 744.29 -1457.17 -249
PER(x) 0 0 0 7.69 8.33 7.18
Price/Book(x) 0 0 0.75 0.47 0.54 0.43
Dividend Yield(%) 0 0 0.94 1.41 1.15 1.37
EV/Net Sales(x) 0.19 0.24 1.78 1.12 1.09 0.85
EV/Core EBITDA(x) 1.54 1.6 12.65 6.79 7.18 5.7
Net Sales Growth(%) 0 11.13 102.15 8.26 10.37 9.71
EBIT Growth(%) 0 46.76 -430.58 188.13 9.13 0.91
PAT Growth(%) 0 27.66 -673.7 151.96 13.16 -2.57
EPS Growth(%) 0 0 -583.1 151.98 13.11 -2.57
Debt/Equity(x) 0.25 0.33 0.17 0.18 0.18 0.19
Current Ratio(x) 1.34 1.22 2.41 2.4 2.18 1.89
Quick Ratio(x) 0.42 0.43 1.27 1.44 1.3 0.96
Interest Cover(x) 6.02 4.35 -4.96 4.49 5.52 4.81
Total Debt/Mcap(x) 0 0 0.23 0.39 0.33 0.44

Nath Bio-Genes Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 45.6 45.6 45.6 45.6 45.6 45.6 45.6 45.6 45.6 45.6
FII 0.32 0.27 0.21 0.18 0.19 0.21 0.41 0.32 0.31 0.22
DII 4.37 4.37 4.37 4.37 4.37 3.95 2.25 0.76 0.01 0.01
Public 49.72 49.76 49.82 49.85 49.84 50.25 51.74 53.32 54.08 54.17
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Nath Bio-Genes News

Nath Bio-Genes Pros & Cons

Pros

  • Stock is trading at 0.5 times its book value
  • Company has delivered good profit growth of 34% CAGR over last 5 years
  • Company is almost debt free.

Cons

  • Promoter holding is low: 45.6%.
  • Company has a low return on equity of 6% over the last 3 years.
  • Debtor days have increased from -1457.17 to -249days.
whatsapp